Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | TNF | P01375 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075342 | 0.96 | CXCR4 (0.49) | CXCR4MEN1MAPK1KMT2ATNF | |
| SCHEMBL4068773 | 0.96 | CXCR4 (0.49) | CXCR4MEN1MAPK1KMT2ATNF | |
| SCHEMBL4077532 | 0.95 | CXCR4 (0.48) | CXCR4MEN1MAPK1KMT2ATNF | |
| SCHEMBL4071713 | 0.90 | CXCR4 (0.51) | CXCR4MEN1MAPK1KMT2AMAPT | |
| SCHEMBL4073359 | 0.90 | CXCR4 (0.53) | CXCR4CYP3A4ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL4067381 | 0.90 | CXCR4 (0.48) | CXCR4MEN1MAPK1KMT2AMAPT | |
| SCHEMBL4066983 | 0.89 | CXCR4 (0.47) | CXCR4MEN1MAPK1KMT2ACYP3A4 | |
| SCHEMBL4069936 | 0.89 | CXCR4 (0.51) | CXCR4MAPK1CYP3A4ALDH1A1CYP2D6 | |
| SCHEMBL4228437 | 0.89 | CXCR4 (0.55) | CXCR4MEN1MAPK1KMT2ATNF | |
| SCHEMBL4072245 | 0.88 | CXCR4 (0.47) | CXCR4MEN1MAPK1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | CXCR4 1/4885MEN1 2211/4885MAPK1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.